HIV-positive patients with virological suppression did not have different rates of aging-relating cognitive decline compared with HIV-negative patients.
HIV-positive individuals with higher alcohol levels performed worse on several cognitive tests, however alcohol was not the primary factor.
HIV patients had reduced brain volume and poorer cognitive performance.
Patients with HIV treated with cART have lower neuropsychological test scores than controls, but no significant neuropsychological decline over time.
Evaluating the risk factors of neurocognitive decline in HIV.
Effective cognitive screening instruments are needed in order to assess and manage milder forms of HIV-associated neurocognitive disorders.
Early detection and robust treatment are critical to limiting deficits in achieving developmental milestones in HIV-infected infants.
The results indicate HERV-K activation as a potential mechanism for HIV-associated ALS.
For the most part, symptoms tend to subside after treatment initiation.
Until now, it was thought that HIV-related inflammation protected the brain from amyloid deposition.
Paroxetine use improved cognitive impairment and reduced inflammation in HIV patients.
The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.
CSF cultures were negative despite worsening meningitis infection.
Researchers are now testing whether antiretroviral drugs used to treat HIV/AIDS are effective in ALS patients.
The findings may have implications for the development of future vaccines.
The new treatment would need to be combined with other HIV drugs or antibodies.
The brain can harbor active HIV even after seemingly successful antiretroviral treatment.
Some coping strategies like substance abuse may have negative affects on overall health.
Neurology Advisor Articles
- US Opioid Overdose Deaths Reach Record Number
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Abnormalities in Genes Linked to IRSP in Alzheimer Disease
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Recommended Levels of Cardiovascular Risk Factors Associated With Cerebral Vessel Density, Flow
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- Cannabidiol Gets Orphan Drug Status for Preventing Ischemia-Reperfusion Injury
- Early Clinical Predictors of Mortality in Parkinson Disease, Parkinsonism
- Lasmiditan NDA Submitted for Acute Treatment of Migraine
- HHS: Updated Physical Activity Guidelines for Americans Released
- 18F-FDG PET Algorithm Allows Early Prediction of Alzheimer's